Skip to main content
    C

    Corvus Pharmaceuticals Inc (CRVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.85
    +0.47 (+5.01%)

    Market Cap: $791.58M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    -12.73%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.22 - $-0.18
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.19-7.9%
    60d ago$-0.19-9.3%
    30d ago$-0.200.0%
    7d ago$-0.200.0%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.28 - $-0.18
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 6
    		$-0.19$-0.17-11.76%Miss-90.0%
    Mar 26
    Reported May 7
    		$-0.15$-0.15+0.00%Beat-7.1%
    Dec 25
    Reported Mar 12
    		$-0.15$-0.13-18.48%Miss-5.0%
    Sep 25
    Reported Nov 4
    		$-0.12$-0.13+7.69%Beat+80.0%
    Jun 25
    Reported Aug 7
    		$-0.10$-0.13+23.08%Beat-42.9%
    Mar 25
    Reported May 8
    		$-0.14$-0.12-16.67%Miss-16.7%
    Dec 24
    Reported Mar 25
    		$-0.14$-0.12-19.08%Miss-2.1%
    Sep 24
    Reported Nov 12
    		$-0.60$-0.12-400.00%Miss-400.0%
    Jun 24
    Reported Aug 6
    		$-0.07$-0.11+36.36%Beat+50.0%
    Mar 24
    Reported May 6
    		$-0.12$-0.13+7.69%Beat+29.4%
    Dec 23
    Reported Mar 19
    		$-0.14$-0.12-16.67%Miss+33.3%
    Sep 23
    Reported Nov 7
    		$-0.12$-0.12+0.00%Beat+62.5%
    Jun 23
    Reported Aug 8
    		$-0.14$-0.14+0.00%Beat+22.2%
    Mar 23
    Reported May 8
    		$-0.17$-0.17+0.00%Beat+5.6%
    Dec 22
    Reported Mar 28
    		$-0.21$-0.23+8.70%Beat-5.0%
    Sep 22
    Reported Nov 3
    		$-0.32$-0.14-128.57%Miss-33.3%
    Jun 22
    Reported Aug 8
    		$-0.18$-0.18+0.00%Beat+35.7%
    Mar 22
    Reported May 5
    		$-0.18$-0.15-20.00%Miss+47.1%
    Dec 21
    Reported Mar 10
    		$-0.20$-0.19-5.26%Miss+39.4%
    Sep 21
    Reported Nov 1
    		$-0.24$-0.24+0.00%Beat+27.3%
    Jun 21
    Reported Aug 2
    		$-0.28$-0.31+9.68%Beat+22.2%
    Mar 21
    Reported Apr 29
    		$-0.34$-0.31-9.68%Miss+22.7%
    Dec 20
    Reported Mar 25
    		$-0.33$-0.32-3.13%Miss+13.2%
    Sep 20
    Reported Oct 29
    		$-0.33$-0.22-50.00%Miss+10.8%
    Jun 20
    Reported Jul 30
    		$-0.36$-0.24-50.00%Miss+18.2%
    Mar 20
    Reported Apr 30
    		$-0.44$-0.40-10.00%Miss-10.0%
    Dec 19
    Reported Mar 5
    		$-0.38$-0.33-15.15%Miss-5.6%
    Sep 19
    Reported Oct 29
    		$-0.37$-0.43+13.95%Beat-2.8%
    Jun 19
    Reported Aug 1
    		$-0.44$-0.44+0.00%Beat-10.0%
    Mar 19
    Reported May 9
    		$-0.40$-0.48+16.67%Beat+36.5%
    Dec 18
    Reported Mar 7
    		$-0.36$-0.46+21.74%Beat+37.9%
    Sep 18
    Reported Nov 1
    		$-0.36$-0.49+26.53%Beat+41.9%
    Jun 18
    Reported Aug 2
    		$-0.40$-0.61+34.43%Beat+45.2%
    Mar 18
    Reported May 3
    		$-0.63$-0.77+18.18%Beat+20.3%
    Dec 17
    Reported Mar 1
    		$-0.58$-0.77+24.68%Beat-5.5%
    Sep 17
    Reported Nov 2
    		$-0.62$-0.84+26.19%Beat-
    Jun 17
    Reported Aug 3
    		$-0.73$-0.74+1.35%Beat-
    Mar 17
    Reported May 4
    		$-0.79$-0.77-2.60%Miss-
    Dec 16
    Reported Mar 10
    		$-0.55$-0.57+3.51%Beat-

    Key Metrics

    Valuation
    P/E Ratio-16.15EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-35.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio16.16xQuick Ratio16.16x
    Trading Statistics
    Beta1.43Avg Volume1.28M
    52-Week High$26.9552-Week Low$6.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.20
    SMA 20$11.12
    SMA 50$12.91
    SMA 200$14.27
    EMA 10$10.23
    EMA 20$10.97
    EMA 50$12.23
    EMA 200$12.58

    MACD

    Line: -0.94Signal: -0.85Hist: -0.09

    ADX

    ADX: 31.4+DI: 17.0-DI: 31.2

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$10.39

    Bollinger Bands

    Upper Band$13.37
    Lower Band$8.88
    %B Position4037%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    32.0

    Momentum Oscillators

    Stoch %K9.4
    Stoch %D7.9
    Williams %R-80.1
    ROC (10d)-9.9%
    Momentum-1.08
    CCI (20d)-98.6
    MFI (14d)26.2

    Volatility Measures

    ATR (14d)$0.65(6.6%)
    StdDev (20d)1.12
    Hist Vol59.4%(High)

    Volume Flow

    VWAP$9.76
    OBV68.3M
    AD Line44.0M
    CMF (20d)-0.003

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.8x
    VWMA (20d)$11.22

    Pivot Points

    R3$9.81
    R2$9.65
    R1$9.52
    Pivot Point$9.36
    S1$9.23
    S2$9.07
    S3$8.94

    Advanced Oscillators

    TSI-40.98
    Ultimate Osc43.1
    KST-231.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$88,000$0$0$0$246,000$0
    Cost of Revenue$0$0$26,000$0$0$0$44,000$0$0$0$28,000$0
    Gross Profit$0$0$-26,000$0$0$0$44,000$0$0$0$218,000$0
    Operating Expenses$19.30M$14.88M$12.22M$10.57M$10.26M$9.92M$8.10M$7.25M$5.93M$6.25M$5.65M$5.56M
    R&D$15.96M$11.18M$9.94M$8.45M$7.87M$7.45M$5.97M$5.22M$4.11M$4.08M$4.00M$3.96M
    SG&A$3.33M$3.70M$2.28M$2.12M$2.39M$2.47M$2.13M$2.03M$1.82M$2.18M$1.65M$1.59M
    Operating Income$-19,297,000$-14,877,000$-12,217,000$-10,572,000$-10,260,000$-9,922,000$-8,105,000$-7,255,000$-5,935,000$-6,253,000$-5,651,000$-5,560,000
    Interest Income$2.05M$1.78M$603,000$738,000$639,000$525,000$508,000$566,000$434,000$316,000$5.06M$-865,000
    Interest Expense$0$0$0$0$0$0$1.83M$32.28M$0$0$0$-425,000
    Income Before Tax$-17,250,000$-13,093,000$-11,614,000$-9,834,000$-7,609,000$15.73M$-9,939,000$-39,535,000$-3,685,000$-5,937,000$-5,249,000$-5,135,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,959,000$-13,692,000$-12,321,000$-10,157,000$-7,998,000$15.19M$-12,113,000$-40,217,000$-4,262,000$-5,701,000$-6,653,000$-6,000,000
    EBITDA$-19,078,000$-14,865,000$-12,452,000$-11,003,000$-8,553,000$14.94M$-10,674,000$-40,604,000$-4,322,000$-6,381,000$-5,750,000$-5,775,000
    EBIT$-19,297,000$-14,877,000$-12,217,000$-10,572,000$-8,248,000$15.21M$-10,452,000$-40,101,000$-4,119,000$-6,253,000$-5,651,000$-5,560,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRVS

    News

    Corvus Pharma Q2 2026 Earnings Call Transcript

    Corvus Pharma reported increased R&D expenses and a net loss in Q2 2026, primarily due to ongoing clinical trials for soquelitinib. The company has a strong cash position, expected to fund operations into Q2 2028...

    Benzinga•10/12/26•Bullish

    Other investing cash flow items (total) of Corvus Pharmaceuticals, Inc. – FWB:C17

    This article provides a financial data point for Corvus Pharmaceuticals, Inc. (FWB:C17), specifically its "Other investing cash flow items (total)." It indicates that the Frankfurt Stock Exchange is currently closed...

    TradingView•10/11/26•Neutral

    One drug is now in trials for four conditions, including a skin disease.

    Corvus Pharmaceuticals has initiated a Phase 1b clinical trial for soquelitinib in patients with moderate to severe hidradenitis suppurativa...

    Stock Titan•10/1/26•Bullish

    Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

    Corvus Pharmaceuticals has initiated a Phase 1b clinical trial for soquelitinib in patients with hidradenitis suppurativa...

    GlobeNewswire•10/1/26•Bullish

    Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

    Corvus Pharmaceuticals has initiated a Phase 1b clinical trial for soquelitinib in patients with hidradenitis suppurativa, an inflammatory skin condition. This trial aims to demonstrate the drug's proof-of-concept...

    Yahoo! Finance Canada•9/30/26•Bullish

    CRVS Valuation and Fair Value

    P/E
    -16.1x
    PEG
    0.0x
    P/B
    4.0x
    See GNG's fair value

    CRVS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -35.4%

    CRVS Competitors

    CompanyTicker
    Ginkgo Bioworks HoldingsDNA
    Varex Imaging CorpVREX
    Esperion Therapeutics IncESPR
    Geron CorporationGERN
    Ardelyx IncARDX
    Candel Therapeutics IncCADL
    P3 Health Partners IncPIII
    Enhabit Inc.EHAB

    Sector: Healthcare

    CRVS Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CRVS Bull Case vs Bear Case

    Bull case

    • 100.0% of CRVS's analyst ratings are Buy or Strong Buy.

    Bear case

    • CRVS beat EPS estimates in 25.0% of its last 8 reported quarters.

    CRVS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -54.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About CRVS

    Does CRVS pay dividends?

    Corvus Pharmaceuticals Inc (CRVS) does not currently pay a regular dividend.

    What is CRVS's market cap?

    Corvus Pharmaceuticals Inc (CRVS) has a market capitalization of $791.58M with a current stock price of $9.85.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In